ORMP · Oramed Pharmaceuticals Inc.
$3.97
-0.20 (-4.80%)
At close · Jul 29
Market Cap
$170.66M
Shares
40.93M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2M
FY2025
Net Income
$64.05M
+436%
FY2025
Gross Margin
0.65%
FY2025
Operating Margin
-754.4%
FY2025
Diluted EPS
$1.50
+412.5%
FY2025
Operating Cash Flow
-$9.15M
-8.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $2M | — | $1.34M | $2.7M | $2.7M | $2.71M | $2.7M | $2.45M | $2.46M | $641K | — | — | — | — | |
| — | $1.99M | — | — | — | — | $90K | $90K | — | $187K | $490K | — | — | — | — | |
| — | $13K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | 0.65% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $5.77M | $6.38M | $6.32M | $8.97M | $27.64M | $20.99M | $10.24M | $13.52M | $11.98M | $10.28M | $7.71M | -$4.78M | $3.28M | $11.8M | $9.53M | |
| $8.48M | $8.72M | $6.46M | $8.43M | $13.81M | $5.94M | $4.23M | $3.72M | $4.08M | $2.76M | $2.45M | -$2.6M | $2.63M | $10.19M | $8.16M | |
| — | — | — | — | — | — | — | — | — | — | — | — | $6000 | — | — | |
| -$14.25M | -$15.09M | -$12.78M | -$15.77M | -$40.6M | -$24.22M | -$11.76M | -$14.63M | -$13.53M | -$10.77M | -$10.01M | $7.38M | -$5.91M | -$22.43M | -$18.13M | |
| — | -754.4% | — | -1176.79% | -1501.96% | -896.15% | -433.84% | -541.29% | -552.35% | -438.56% | -1561.62% | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$5.9M | — | — | |
| — | — | $853K | $2.04M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | $10K | — | — | — | — | — | — | — | — | — | — | — | |
| $136.86M | $89.45M | -$2.29M | $22.89M | $2.93M | — | — | — | — | — | — | — | — | — | — | |
| $131.82M | $75.32M | -$15.92M | $5.09M | -$37.66M | — | -$11.51M | -$14.06M | -$12.73M | -$10.08M | -$9.63M | $7.23M | -$5.69M | -$22.09M | -$17.65M | |
| $21.85M | $11.31M | $3.18M | — | $100K | — | $300K | $300K | $400K | $400K | $1.34M | $1000 | $4000 | $35.71K | $240.78K | |
| $110M | $64.05M | -$19.06M | $5.09M | -$36.56M | -$22.99M | -$11.51M | -$14.36M | -$12.73M | -$10.48M | -$10.96M | $7.23M | -$5.7M | -$22.12M | -$17.89M | |
| — | 3202.5% | — | 379.7% | -1352.61% | -850.5% | -424.76% | -531.08% | -519.68% | -426.71% | -1710.45% | — | — | — | — | |
| — | -$34K | -$43K | $437K | -$1.2M | — | — | — | — | — | — | — | — | — | — | |
| — | $63.24M | -$19.06M | — | -$36.56M | $22.99M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $22.24M | -$11.51M | -$14.36M | -$12.43M | -$10.19M | -$11.42M | $7.13M | -$5.55M | -$21.82M | -$16 | |
| USD/shares | — | $1.53 | -$0.48 | $0.14 | -$0.94 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | $1.50 | -$0.48 | $0.14 | -$0.94 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 41.4M | 40.85M | 40.32M | 39M | 28.47M | 20.53M | 17.45M | 14.88M | 13.31M | 12.62M | 10.82M | 9.24M | 7.21M | — |
| shares | — | 42.42M | 40.85M | 40.57M | 39M | 28.47M | 20.53M | 17.45M | 14.88M | 13.31M | 12.62M | 10.82M | 9.24M | 7.21M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $7.23M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.85×
EV/EBIT
—
Peer median 26.86×
P/E (TTM)
1.60×
Peer median 4.43×
Peer medians compare against the 303 similar-size Biotechnology companies (of 522 listed).
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1176309
CUSIP
68403P203
13F (30d)
11 filings
11 filers
Visit website
Investor relations